Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Igloo: Laninamivir Octanoate for Influenza
NCT01793883Phase 2Completed
- Sponsor
- Biota Holdings Limited
- Start
- May 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of laninamivir octanoate in influenza (3 arms), sponsored by Biota Holdings Limited. Primary endpoint: Time to Alleviation of Influenza Symptoms at 14 days. Started May 2013; status: completed.
02
Drugs
laninamivir octanoate
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01793883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01793883.